EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Microbiome and Prostate Cancer: Emerging Diagnostic and Therapeutic Opportunities

Sung Jin Kim, Myungchan Park iD, Ahnryul Choi, Sangjun Yoo

Pharmaceuticals · 13.01.2024 · 17 (1) · 112

DOI: 10.3390/ph17010112 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 13.01.2024. Verfasst von Sung Jin Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung 25440, Republic of Korea. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technology Innovation Pro-398 gram funded by the Ministry of Trade, Industry and Energy (MOTIE), "Regional Innovation Strategy (RIS)" through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (MOE) in 2023, Ministry of Education (MOE).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review systematically addresses the correlation between the microbiome and prostate cancer and explores its diagnostic and therapeutic implications. Recent research has indicated an association between the urinary and gut microbiome composition and prostate cancer incidence and progression. Specifically, the urinary microbiome is a potential non-invasive biomarker for early detection and risk evaluation, with altered microbial profiles in prostate cancer patients. This represents an advancement in non-invasive diagnostic approaches to prostate cancer. The role of the gut microbiome in the efficacy of various cancer therapies has recently gained attention. Gut microbiota variations can affect the metabolism and effectiveness of standard treatment modalities, including chemotherapy, immunotherapy, and hormone therapy. This review explores the potential of gut microbiome modification through dietary interventions, prebiotics, probiotics, and fecal microbiota transplantation for improving the treatment response and mitigating adverse effects. Moreover, this review discusses the potential of microbiome profiling for patient stratification and personalized treatment strategies. While the current research identifies the pivotal role of the microbiome in prostate cancer, it also highlights the necessity for further investigations to fully understand these complex interactions and their practical applications in improving patient outcomes in prostate cancer management.

Schlagwörter

Stichwörter der Autor:innen

gut microbiomeprostate cancerurine microbiome

Autor:innen und Institutionen

  • Department of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung 25440, Republic of Korea.
  • Department of Urology, Haeundae Paik Hospital, Inje University College of Medicine, Busan 47392, Republic of Korea.
  • Department of Biomedical Engineering, College of Medical Convergence, Catholic Kwandong University, Gangneung 25601, Republic of Korea.
  • Department of Urology, SNU-SMG Boramae Medical Center, Seoul 07061, Republic of Korea.

ORCID-Profile: Myungchan Park

Förderung

  • Technology Innovation Pro-398 gram funded by the Ministry of Trade, Industry and Energy (MOTIE)
  • "Regional Innovation Strategy (RIS)" through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (MOE) in 2023
  • Ministry of Education (MOE)
  • Ministry of Trade, Industry and Energy (MOTIE)

Zitieren

APA

Kim, S. J., Park, M., Choi, A., & Yoo, S. (2024). Microbiome and Prostate Cancer: Emerging Diagnostic and Therapeutic Opportunities. Pharmaceuticals, 17(1), 112. https://doi.org/10.3390/ph17010112

Vancouver

Kim SJ, Park M, Choi A, Yoo S. Microbiome and Prostate Cancer: Emerging Diagnostic and Therapeutic Opportunities. Pharmaceuticals. 2024;17(1):112. doi:10.3390/ph17010112

BibTeX
@article{Kim2024,
  author = {Kim, Sung Jin and Park, Myungchan and Choi, Ahnryul and Yoo, Sangjun},
  title = {Microbiome and Prostate Cancer: Emerging Diagnostic and Therapeutic Opportunities},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {1},
  pages = {112},
  doi = {10.3390/ph17010112}
}
Kostenlos starten →